Numerous reports have confirmed that the efficacy of EGFR-TKIs correlates with EGFR exon mutations [5], [8], and that the incidence of EGFR mutations is higher among Asians, non-smokers, females, and patients with adenocarcinoma. The gene discussed is EGFR; the disease is adenocarcinoma.